# vomiting
reference list for Viral mOlecular methods and Models that Inform Transmission of INfectious Gastroenteritis (VOMITING) initiaitive

[1]	T. Nakagomi, K. Kato, H. Tsutsumi, and O. Nakagomi, ‘The Burden of Rotavirus Gastroenteritis among Japanese Children during Its Peak Months: an Internet Survey’, Jpn. J. Infect. Dis., vol. 66, no. 4, pp. 269–275, Jul. 2013.
[2]	C.-H. Chang, M. Sakaguchi, J. Weil, and T. Verstraeten, ‘The incidence of medically-attended norovirus gastro-enteritis in Japan: Modelling using a medical care insurance claims database’, Plos One, vol. 13, no. 3, p. e0195164, Mar. 2018.
[3]	T. G. Phan et al., ‘Outbreak of sapovirus infection among infants and children with acute gastroenteritis in Osaka City, Japan during 2004-2005’, J. Med. Virol., vol. 78, no. 6, pp. 839–846, Jun. 2006.
[4]	S. Ohfuji et al., ‘Nationwide epidemiologic study of norovirus-related hospitalization among Japanese older adults’, Bmc Infect. Dis., vol. 19, p. 400, May 2019.
[5]	T. Sato, T. Nakagomi, and O. Nakagomi, ‘Cost-Effectiveness Analysis of a Universal Rotavirus Immunization Program in Japan’, Jpn. J. Infect. Dis., vol. 64, no. 4, pp. 277–283, Jul. 2011.
[6]	C. Troeger et al., ‘Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016’, Lancet Infect. Dis., vol. 18, no. 11, pp. 1211–1228, Nov. 2018.
[7]	S. Ramani, R. L. Atmar, and M. K. Estes, ‘Epidemiology of human noroviruses and updates on vaccine development’, Curr. Opin. Gastroenterol., vol. 30, no. 1, p. 25, Jan. 2014.
[8]	K. Nagasawa et al., ‘Genetic Analysis of Human Norovirus Strains in Japan in 2016–2017’, Front. Microbiol., vol. 9, Jan. 2018.
[9]	T. Motoya et al., ‘Variation of human norovirus GII genotypes detected in Ibaraki, Japan, during 2012–2018’, Gut Pathog., vol. 11, May 2019.
[10]	‘WHO | Global use of rotavirus vaccines recommended’, WHO. [Online]. Available: https://www.who.int/mediacentre/news/releases/2009/rotavirus_vaccines_20090605/en/. [Accessed: 29-Aug-2019].
[11]	S.-L. Hoshi, M. Kondo, and I. Okubo, ‘Economic evaluation of routine infant rotavirus immunisation program in Japan’, Hum. Vaccines Immunother., vol. 13, no. 5, pp. 1115–1125, 04 2017.
[12]	T. Sato, T. Nakagomi, and O. Nakagomi, ‘Cost-Effectiveness Analysis of a Universal Rotavirus Immunization Program in Japan’, Jpn. J. Infect. Dis., vol. 64, no. 4, pp. 277–283, Jul. 2011.
[13]	S. L. Thomas et al., ‘Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted’, Vaccine, vol. 35, no. 4, pp. 680–686, 23 2017.
[14]	C. J. Atchison et al., ‘Rapid Declines in Age Group-Specific Rotavirus Infection and Acute Gastroenteritis Among Vaccinated and Unvaccinated Individuals Within 1 Year of Rotavirus Vaccine Introduction in England and Wales’, J. Infect. Dis., vol. 213, no. 2, pp. 243–249, Jan. 2016.
[15]	S. L. Pollard, T. Malpica-Llanos, I. K. Friberg, C. Fischer-Walker, S. Ashraf, and N. Walker, ‘Estimating the herd immunity effect of rotavirus vaccine’, Vaccine, vol. 33, no. 32, pp. 3795–3800, Jul. 2015.
[16]	M. Jit et al., ‘The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe’, Vaccine, vol. 27, no. 44, pp. 6121–6128, Oct. 2009.
[17]	S. Flasche et al., ‘Early indication for a reduced burden of radiologically confirmed pneumonia in children following the introduction of routine vaccination against Haemophilus influenzae type b in Nha Trang, Vietnam’, Vaccine, vol. 32, no. 51, pp. 6963–6970, Dec. 2014.
[18]	‘VIEW-hub : Home’. [Online]. Available: http://www.view-hub.org/. [Accessed: 29-Aug-2019].
[19]	S.-L. Hoshi, M. Kondo, and I. Okubo, ‘Economic evaluation of routine infant rotavirus immunisation program in Japan’, Hum. Vaccines Immunother., vol. 13, no. 5, pp. 1115–1125, 04 2017.
[20]	M. Paulke-Korinek et al., ‘Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria’, Vaccine, vol. 29, no. 15, pp. 2791–2796, Mar. 2011.
[21]	D. Poelaert, P. Pereira, R. Gardner, B. Standaert, and B. Benninghoff, ‘A review of recommendations for rotavirus vaccination in Europe: Arguments for change’, Vaccine, vol. 36, no. 17, pp. 2243–2253, Apr. 2018.
[22]	M. Jit and M. Brisson, ‘Modelling the Epidemiology of Infectious Diseases for Decision Analysis’, PharmacoEconomics, vol. 29, no. 5, pp. 371–386, May 2011.
[23]	J. E. Tate et al., ‘Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000–2013’, Clin. Infect. Dis., vol. 62, no. suppl_2, pp. S96–S105, May 2016.
[24]	Y. Kawamura, M. Ohashi, M. Ihira, S. Hashimoto, K. Taniguchi, and T. Yoshikawa, ‘Nationwide survey of rotavirus-associated encephalopathy and sudden unexpected death in Japan’, Brain Dev., vol. 36, no. 7, pp. 601–607, Aug. 2014.
[25]	K. Araki et al., ‘Estimating rotavirus vaccine effectiveness in Japan using a screening method’, Hum. Vaccines Immunother., vol. 12, no. 5, pp. 1244–1249, Dec. 2015.
[26]	T. Shiroiwa, T. Fukuda, S. Ikeda, T. Takura, and K. Moriwaki, ‘Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan’, Value Health, vol. 20, no. 3, pp. 372–378, Mar. 2017.


